In the middle of July 2024, the new version of the classification of procedure codes (CCAM v.76) was published. Several changes were introduced, including creating 14 new codes in diagnostic imaging, men’s health, and neuromodulation technology groups.

On July 12, 2024, the UK National Screening Committee (UK NSC) announced a new task group for multi-cancer detection (MCD) tests. The group will review different methods for the evaluation of MCDs, from which UK NSC is expected to derive a position statement and develop a roadmap for a possible MCD screening program.

The new framework agreement on the medical devices included in the LPPR was signed on July 2, 2024.

On July 9, 2024, the updated Finnish classification of procedures (THL) was published to come into force on August 1, 2024. Forty-three new procedure codes were implemented concerning diagnostic imaging, nuclear medicine, neurovascular, radiology, and other fields.

Our goal at MTRC is to inform the decision-making of our clients and to support their market access activities. Below is a snapshot of our planned activities for the next two weeks. This can help our existing and prospective clients to better understand the potential scope of our support. From the week of 29th of July, we are planning to work on 21 projects. Review the full list of planned activities in this post.

On July 16, 2024, the French Ministry of Labor, Health and Solidarity published the merged 2024 List of acts outside the nomenclature financed under MERRI G03.

In July 2024, the National Institute for Health and Disability Insurance (INAMI-RIZIV) approved a new agreement (Convention) allowing reimbursement for percutaneous CT-guided ablation of renal, hepatic, pulmonary, and bone tumors. The agreement will come into force on November 1, 2024, and will be valid until October 31, 2029.

On July 15, 2024, the Austrian Institute for HTA (AIHTA) published three decision support documents that provide recommendations regarding the inclusion of new medical interventions in the catalog of individual medical services (MEL) for reimbursement, as well as two updates to previous decision support documents. The decisions relate to cardiovascular, peripheral vascular, interventional radiology, neuromodulation, and endocrine technology groups.

In late June – mid-July 2024, the Innovation Committee at the Federal Joint Committee (G-BA) published the decisions recommending the transfer to standard care for another three completed projects. The projects were dedicated to the topics of care concept for patients with hidradenitis suppurativa (acne inversa), the use of webcams in neonatal intensive care units, and improving the pharmacovigilance of innovative therapies.

On June 26, 2024, the Norwegian Directorate of Health published its proposal to change the process of including new diseases in newborn screening. The key objective is making the process more dynamic, which requires regulatory and administrative amendments.

On June 19, 2024, the Order SND/606/2024, of June 13, came into force. This Order, among other things, creates the Advisory Committee for the Common Package of Benefits in the Area of Genetics.

On June 21, 2024, the Innovation Committee at the Federal Joint Committee (G-BA) published the determined funding priorities for healthcare research projects (eight topics) and clinical guidelines (three topics).